J R Soc Med 2004;97:103-110
doi:10.1258/jrsm.97.3.103
© 2004 Royal Society of Medicine
The epidemic of asthma and allergy
Stephen T Holgate DSc FRCP
Respiratory Cell & Molecular Biology Division, School of Medicine,
University of Southampton, Southampton General Hospital, Southampton SO16 6YD,
UK
E-mail:
s.holgate{at}soton.ac.uk
 |
INTRODUCTION
|
|---|
In his treatise
On Asthma: Its Pathology And Treatment first
published
in 1860, Henry Hyde Salter
(
Figure 1), a physician at the
Charing
Cross Hospital, London, differentiated asthma from other causes
of
breathlessness as `paroxysmal dyspnoea of a peculiar character
with intervals
of healthy respiration between
attacks'.
1 6 years
later,
from an analysis of 150 unpublished cases, he described many
of the
characteristic features of this disease including hyperresponsiveness
to cold
air and exercise and attacks provoked by exposure to
chemical and mechanical
irritants, to particular kinds of air
as well as to certain foods and
wine.
2,3
His observations were
further enhanced by the use of the spirograph, the
earliest
record of a water
spirometer.
4 In
these publications Salter
identified asthma as a spasmodic stricture occurring
throughout
the conducting airways, and differentiated the condition from
bronchial
catarrh, recent bronchitis and old bronchitis
(
Figure 2). He
drew special
attention to the musical rhonchus that characterized
asthmatic
bronchoconstriction and indicated that the sibilant
bronchi could not be
relieved by coughing. Also of great significance
was his observation of cells
in the asthmatic sputum, which
he identified by the presence of a nucleus,
nucleolus and cell
wall. The identification of eosinophils in sputum had to
await
the development of eosin by Paul Ehrlich some 15 years
later.
5 Sir William
Osler, in his first edition of
Principles and Practice of
Medicine,6
likewise drew attention to the factors that could
exacerbate asthma including
allergens, air pollutants, infections,
exercise, weather, food and
emotions.
Hyperresponsiveness of the conducting airways, a characteristic feature of
all forms of asthma, can be quantified in the laboratory by use of inhalation
bronchial provocation tests with such agents as methacholine and histamine. In
asthma the doseresponse curve to these agonists is displaced to the
left in proportion to disease severity, and at high agonist concentrations
there is loss of the normal protective plateau
(Figure 3). As pointed out by
both Salter and Osler, hyperresponsiveness is in part the result of a
characteristic type of inflammation that affects the conducting airways and is
accompanied by marked structural changes to the airways which include an
increase in airway smooth muscle and deposition of matrix leading to an
overall thickening of the airway wall (remodelling). The pathological features
of asthma are vividly illustrated by Huber and Koessler in their classic paper
of 1922.7 These
combine to make the airways contract too much and too easily in response to
exogenous and endogenous stimuli, as well as contributing to the diurnal
variation in airway calibre that is characteristic of the disease.

View larger version (19K):
[in this window]
[in a new window]
|
Figure 3. Typical doseresponse curves in normal and asthmatic individuals
on aerosol bronchial provocation with increasing concentrations of
methacholine
|
|
Today, fibreoptic bronchoscopy allows ready access to airways, and lavage
and mucosal biopsy samples confirm the presence of a special type of
inflammation characterized by infiltration of the airway wall with activated T
lymphocytes, mast cells, basophils, eosinophils and macrophages. In addition,
morphometric studies on airways from patients who have died from or with
asthma have quantified the impressive increase in airway smooth muscle that
occurs in this disease, along with structural changes that include shedding of
epithelial cells and epithelial mucous metaplasia, deposition of collagen and
other matrix proteins in the lamina reticularis beneath a normal epithelial
basement membrane, increased deposition of proteoglycans and repair collagen
throughout the airway wall, and an increase in submucosal microvessels and
nervesall changes tantamount to airway remodelling. The fact that these
structural changes occur in early childhood, at the inception of
asthma,8 indicates
that they are fundamental to pathogenesis and occur parallel to, rather than
as a consequence of, airway
inflammation.9
 |
THE RISING TRENDS OF ASTHMA AND ALLERGY
|
|---|
The past three decades have witnessed a spectacular increase
in the
prevalence of asthma and allergic disease worldwide,
especially in those
countries with a Western
lifestyle.
10 In
the
International Study of Asthma and Allergy in Children, the
highest prevalences
of asthma were in Australia, New Zealand
and the UK, where in 2003 more than
20% of children aged 1314
years reported asthma
symptoms.
11 By
contrast, in Central Africa,
Central and Eastern Europe and China the
prevalence of childhood
asthma was less than 5%. The European Community
Respiratory
Health
Survey
12 has
revealed similar intercountry differences
in prevalence of adult asthma and
bronchial hyperresponsiveness.
While part of the explanation for these wide
differences in
disease prevalence may be genetic, in that those countries with
the
highest disease prevalence were host to large migrations of
people from
the UK, a critical role for environmental factors
in driving the expression of
asthma and other allergic diseases
is almost
certain.
10 This
argument is made all the more compelling
by the observation that, in countries
where prevalence studies
have been conducted by identical methods over a span
of 1025
years, the disease prevalence has increased progressively in
children,
adolescents and adults (
Figure
4).
13

View larger version (11K):
[in this window]
[in a new window]
|
Figure 4. The rising trends in asthma in different countries. The paired
prevalence rates in each country were obtained with the same instruments
|
|
Clues to the environmental factors that drive the rising trends may be had
from a closer look at disease mechanisms. With the recognition that
geneenvironmental interactions are critical to the pathogenesis of
allergic disorders such as asthma, there has been a major focus on the
immunological and inflammatory mechanisms that underlie the origins of allergy
and its progression to allergic inflammation. It was Charles Harrison Blackley
(Figure 5) in Experimental
Researches on the Cause and Nature of Catarrhus Aestivus
(1873)14 who drew
our attention to the importance of pollen exposure as a causal factor in
hayfever and `hay asthma'. Having installed the world's very first pollen
counter on the roof of his house in Manchester, Blackley was able to show
clearly that his own symptoms of rhinitis and asthma coincided exactly with
the peak increase in the count of pollen grains collected over each
twenty-four hours across June and July. In the closing paragraph of his
monograph14 he
states:
`I am, as I have intimated, quite aware that other agents may yet be found
to produce symptoms not unlike those of hayfever. Amidst the great number of
bodies there are with functions similar to those of pollen, it would not be
surprising if we should find some that have a similar kind of action; and it
is not improbable that among these, we may find the exciting causes of some
diseases which are far more formidable than hayfever.'
How right he was. Some 20 years later, Osler drew attention to the
importance of house dust as a trigger of both rhinitis and asthma. The
identification of the dust mites Dermatophagoides pteronyssinus and
D. farinae (or rather their faeces) as causal agents led to extensive
research on the environmental factors most conducive to dust mite reproduction
and survival as well as on the substances that lead to an allergic response.
We now know that such allergens, whether in mite faeces or other sources such
as pollen grains, fungal hyphae or animal material, may have intrinsic
biological properties, including proteolytic enzyme activity, that help them
penetrate epithelial barriers and gain access to the mucosal or epidermal
tissue where they evoke the allergic
response.15 In
countries with a high prevalence of allergic disease, up to 40% of the
population are sensitized to common environmental allergens such as grass and
tree pollen, dust mite excreta and animal materials, the highest prevalence of
sensitization being found in those countries with the greatest incidence of
allergic disease.
 |
IMMUNOLOGICAL BASIS FOR ASTHMA AND ALLERGY
|
|---|
Sensitization to allergens usually starts at mucosal or dermal
surfaces
when the allergen is taken up by antigen presenting
cells (APCs; dendritic or
Langerhans cells). In genetically
susceptible individuals, selective peptides
are generated by
APCs and presented to naïve T lymphocytes in local
lymphoid
tissue
16
which then multiply and differentiate into a subtype
of T cells designated
Th2-like.
17 In
addition to being implicated
in the pathogenesis of allergy and asthma,
Th2-like cells are
fundamental to the development of an effective immune
response
against
parasites.
18 It
would seem that in the Western world
this arm of the immune response has been
highjacked by environmental
allergens, leading to specific sensitization and
allergic disease.
A second set of T lymphocytes designated Th1-like with
capacity
to secrete interferon

(IFN-

) negatively regulates the
ability
of Th2-like cells to develop. In babies born to families with
a strong
history of allergic disease, there exists a defect
in the Th1 arm of the
immune response with a consequent increase
in Th2
responsiveness.
19
More recently, additional T lymphocyte
subsets designated regulatory T cells
(T reg cells) and Th3-like
cells have been found to modify the extent of both
Th1 and Th2
responses through their ability to secrete anti-inflammatory
cytokines,
transforming growth factor ß (TGF ß) and
interleukin 10,
thereby adding a further level of complexity
to T cell mediated immune
regulation (
Figure
6).
20

View larger version (43K):
[in this window]
[in a new window]
|
Figure 6. The role of cytokines in directing the balance between T lymphocyte
subsets. Th2-like T cells orchestrate the inflammatory response of asthma
and allergy. T reg and Th3 inhibit both Th1 and Th2 responses
|
|
| Box 1 Influence of infection in protecting against allergy
- Strong socioeconomic gradient
- Less allergy in large families
- Less allergy in lastborn siblings
- Less allergy in rural than urban environments
- Less allergy in developing countries
- Less allergy in relation to gastrointestinal infectionse.g.
hepatitis A, toxoplasmosis, Helicobacter pylori
- Less allergy in children attending daycare centres
- Less allergy in children attending Steiner schools
|
The expansion of Th2-like T cells occurs in the local lymphoid
tissuei.e. the site of antigen presentation. The net result of this
process is the coordinate secretion of a range of small-molecular-weight
cytokines encoded in a cluster on chromosome 5q31-34 (including interleukins
3, 4, 5, 6, 9 and 13 and granulocytemacrophage colony stimulating
factor) with the capacity to induce the lymphocytes to switch from making IgM
to making the allergic antibody IgE (interleukins 4 and 13), and encourage the
migration and maturation of tissue mast cells (interleukins 3, 4, 6, 9, 13).
Th2 cytokines also upregulate the expression of specific adhesion molecules
(vascular cell adhesion molecule 1 and intercellular adhesion molecule 1) on
microvascular endothelial cells which trap and activate passing leukocytes,
specifically eosinophils, basophils and
monocytes.21 The
mast cell is particularly important in initiating the allergic response,
because cross-linking of the IgE bound to the surface of these cells produces
an explosive release of granule-associated and newly formed chemical mediators
and cytokines which interact with constituent cells in smooth muscle, nerves,
blood vessels and mucus glands to produce the clinical manifestations of
allergy.
 |
PREVENTION OF ALLERGY BY REDUCING EXPOSURE TO ALLERGENS
|
|---|
An obvious way to prevent allergic disease in high-risk individuals,
or to
prevent or reverse symptoms, is to restrict contact with
an offending
allergen. In some cases separation of a sensitized
individual from an
offending allergen (e.g. a laboratory worker
sensitized to rodent allergens)
can produce a dramatic effect,
but in other circumstances the results are less
impressive.
This is particularly the case for house dust mite avoidance.
Some
workers argued strongly that encasement of bedding with
dust mite impermeable
materials, together with measures to reduce
dust mite exposure in the bedroom
and living area of the house,
would have a major impact in reducing
sensitization and subsequent
development of allergic disease, as well as
reducing symptoms
in those already sensitized. However, primary prevention
studies
in
infants
22 and the
use of reasonable (but not exhaustive)
dust mite avoidance strategies in
adults have proved
disappointing.
23,24
In
children with dust mite related asthma and eczema, mite reduction
strategies
have been reported to be more
successful.
25,26
 |
THE HYGIENE HYPOTHESIS
|
|---|
Exposure to increased amounts of allergens, such as those derived
from
house dust mite, may account for some of the increase in
allergy seen in
countries with a Western lifestyle. In Australia,
a rise in dust mite exposure
has been linked to the sealing
of air conditioned houses and the use of soft
furnishings, but
increased exposure to allergens cannot explain the large
inter-country
differences in allergic disease and allergen sensitization,
nor
the rising trends. In 1989 David
Strachan
27 stated,
on the
basis of epidemiological work, that `the apparent rise [in the
prevalence
of allergic disease]... could be explained if allergic diseases
were
prevented by infection in early childhood, transmitted by unhygienic
contact
with older siblings, or acquired prenatally...'. Since that
time
extensive epidemiological research has shown that exposure
to microorganisms
or their products may account in part for
the rising trends in allergic
disease. Some the findings are
summarized in Box 1. A particularly striking
observation is
that, compared with children in the general population,
children
brought up on livestock farms (and thus in frequent contact
with farm
animals) have a 5075% reduction in the prevalence
of allergic disease
such as hayfever in parallel with a reduction
in sensitization to common
environmental
allergens.
28 A key
question
arising from these studies is how exposure to microorganisms
is able
to protect children from allergic sensitization. Bacterial
cell walls contain
complex endotoxins such as lipopolysaccharides
(Gram-negative bacteria) and
muramic acid (Gram-positive bacteria);
fungal spores and hyphae contain
chitin; bacteria contain unmethylated
CpG DNA sequences; and viruses contain
double-stranded RNA.
Each of these substances is able to stimulate specific
toll-like
receptors (TLRs) on antigen presenting cells. Viral double-stranded
RNA
activates TLR3, lipopolysaccharide activates TLR4 and CpG activates
TLR9.
Activation of TLRs directs a protective immune response
by upregulating the
expression of Th1, Th3 and Treg T lymphocytes,
thereby inhibiting Th2 mediated
allergic
sensitization.
20
The
importance of these mechanisms is illustrated by the work of
Braun-Fährlander
and colleagues showing that, in children brought up in a
rural
environment, the endotoxin load in their mattresses is inversely
related
to the occurrence of hayfever, hayfever symptoms and
grass
sensitization.
29 As
an extension of these ideas Donata
Vercelli has advanced the concept of the
endotoxin `switch'whereby
in children born of allergic parents who
exhibit a defective
Th1 response, exposure to the contents of microorganisms
through
the activation of TLRs (part of the innate immune response)
is able to
compensate by enhancing Th1-like responses with consequent
reduction of Th2
responses.
30
With recognition of the importance of TLRs as an integral component of the
innate immune response involved in protection against allergic disease,
attempts are being made to harness these mechanisms in the form of vaccine
development.31 When
conjugated to the oligonucleotide CpG, the major ragweed allergen Amb
a1 is 100-fold less allergenic than unlinked Amb a1 in those
sensitized to ragweed and has been shown to give total protection against
ragweed during the pollen season in the
USA.32 Studies such
as these, as well as the use of CpG alone or given as a mixture along with an
allergen or a peptide derived from the allergen, are being investigated in
human clinical trials following very promising results in
animals.33,34
 |
IgE AS A THERAPEUTIC TARGET
|
|---|
IgE, originally described as `reagin' by Prausnitz and Küstner
in
1922,
35 is the
principal trigger for an allergic tissue response
on exposure to a specific
allergen. Since the molecular identification
in 1968 of reagin as the fifth
immunoglobulin,
36,37
IgE has
been a major target for development of treatment. IgE directed
to
specific allergens binds strongly to the high affinity IgE
receptor
(FC

R1-

ß
2) present on mast cells and
basophils.
Cross-linkage of adjacent IgE molecules by prevailing allergen
results
in dimerization of the receptors and cell activation with secretion
of
various inflammatory mediators and
cytokines.
38
Administration
of a humanized monoclonal antibody against the C

3 region
of
IgE, the component that binds to the

-chain of FC

R1, results
in
sequestration of circulating
IgE
39 with eventual
loss of IgE
binding to cells within
tissues.
40 The
anti-IgE itself will
not activate IgE bound to its receptors or mast cells or
basophils
since the epitope against which the antibody is directed is
obscured
by binding to the FC

R1 receptor
(
Figure
7).
41
Anti-IgE
(omalizumab) has yielded striking clinical improvement in adults
and
children with steroid-requiring
asthma
42,43
and has recently
been approved for clinical use in the USA. Bronchial biopsies
from
asthmatic patients receiving omalizumab for twelve weeks demonstrated
a
pronounced reduction in airway inflammation (including eosinophils)
in
parallel with a loss of IgE and its receptor from mast
cells.
40 This
exciting therapeutic approach to asthma and allergy is
now being followed by
generation of peptide vaccines with the
capacity to induce a therapeutic
antibody response to cell IgE
C

3 domain by coupling non-self protein or
peptide to self structures.
These second-generation vaccines have proven to be
highly effective
in non-human primate models of allergic disease and are about
to
enter clinical
trials.
44

View larger version (49K):
[in this window]
[in a new window]
|
Figure 7. The inhibitory effect of the anti-human IgE monoclonal antibody
omalizumab on the allergic cascade
|
|
 |
TISSUE SUSCEPTIBILITY FACTORS IN ASTHMA
|
|---|
While IgE-dependent sensitization and subsequent allergic inflammation
in
the lower airways is undoubtedly important in asthma pathogenesis,
the picture
changes with disease progression: as the disease
becomes more severe and
chronic (and therefore refractory to
corticosteroids) the structural elements
of the airway wall,
including airway smooth muscle, contribute more to the
clinical
expression of the disease than does the inflammation. In structural
studies
a close correlation has been seen between the thickness of the
lamina
reticularis (beneath the airway epithelium) and the thickness
of the airway
wall and amount of smooth
muscle.
45 In infant
rhesus
monkeys, exposure to house dust mite allergens results in thickening
of
the lamina reticularis and a parallel increase in airway
smooth muscle bundle
orientation and thickness in the larger
airways.
46 These
structural changes are accompanied, in the `asthmatic'
monkeys, by a large
increase in airway hyperresponsiveness as
well as an increase in
mucus-secreting goblet cells in the airway
epithelium. If allergen-exposure is
discontinued after the first
six months of life, there is no reversal of the
lamina reticularis
thickening or of the accompanying increase in airway smooth
muscle,
even after 2
years.
47 This
points to the importance of susceptibility
genes not only in the development
of the allergic response but
also in determining the tissue response to
allergic processes.
 |
ADAM33THE FIRST NOVEL ASTHMA GENE
|
|---|
In collaboration between the Genome Therapeutic Corporation,
Schering-Plough
Research Institute, USA and the University of Southampton, we
have
undertaken a positional cloning effort to identify novel susceptibility
genes
involved in the development and progression of asthma
(
Figure
8).
48
It
has long been known that, although asthma and allergies run
in families,
bronchial hyperresponsiveness and allergy are separate
genetic traits that are
inherited independently. Genetic modelling
has shown that asthma is a complex
disease involving several
genes with moderate effect and important
interactions with the
environment. In 480 families with two or more affected
asthmatic
children, a genome-wide screen involving microsatellite markers
led
to the identification of a major area of linkage between
asthma and bronchial
hyperresponsiveness on chromosome 20p13.
Through physical mapping of the
region and identification of
the genes underlying the peak of linkage by use
of bacterial
artificial chromosomes, 40 genes were within the 90% confidence
interval.
Subsequent casecontrol and family-based transmission
disequilibrium
test (TDT) association mapping led to the identification of
a
disintegrin and metalloprotease (ADAM) gene as responsible
for the linkage
signal.
ADAM33 is a complex molecule whose expression
is restricted
largely to mesenchymal cells including fibroblasts
and smooth
muscle.
48,49
It is made up of five domainsactivation,
proteolytic, adhesion, fusion,
and signalling. Single nucleotide
polymorphisms that are most strongly
associated with asthma
in our original study have been shown, in asthmatic
adults,
to predict rapid decline in lung function over a 20-year
interval
50 and, in
children with allergic and asthmatic parents, impaired
lung function at ages 3
and 5 years.
51 The
precise mechanism
whereby polymorphic variation in
ADAM33 is
associated with asthma
is not known, although removal of the gene's function
by means
of antisense oliognucleotides appears to prevent the differentiation
of
airway fibroblasts into a contractile phenotype (myofibroblasts)
when
incubated
in vitro with the profibrogenic growth factor
TGF-ß.
In addition to
ADAM33, two asthma genes have
been described by the
Oxford group
PHF-11
52 and
DPP-1253both
involved
in amplifying IgE and Th2 mediated inflammation.
 |
CONCLUSIONS
|
|---|
From the extraordinarily perceptive clinical and physiological
observations
made by Salter, Blackley, Osler, Ehrlich, Prausnitz,
Küstner the
Ishizakas and Johannsson, the foundations for
the scientific basis of allergic
disease and asthma have been
laid. The application of modern molecular
medicine to well phenotyped
patients will undoubtedly lead to the
identification of new
molecules fundamental to the pathogenesis of complex
diseases
such as asthma. However, the real challenge for the future is
to
understand how the changing environment associated with the
Western culture is
leading to altered expression of these genes
and a prevalence of serious
allergic disease that in the UK
is reaching epidemic
proportions.
52 The
increasing recognition
that both inflammatory and structural changes are
needed in
teh airways, for asthma to become fully manifest in its chronic
form,
is opening the debate as to which environmental factors are
critical to
the inception and progression of the disease in
genetically susceptible
individuals. It is through understanding
of the interplay between these
factors that we can hope for
better means of prevention and treatment, and
even cure.
 |
REFERENCES
|
|---|
- Salter HH. On Asthma: Its Pathology and
Treatment. London: John Churchill, 1860
- Salter H. An analysis of a hundred and fifty unpublished cases of
asthma No 1. The influence of sex and age in determining the liability to
asthma. Lancet1866; ii:90
1
- Salter H. An analysis of a hundred and fifty unpublished cases of
asthma No 2. On the immediate excitants of the asthmatic paroxysm.
Lancet1866; ii:259
60
- Salter H. Lectures on dyspnoea Lecture 3.
Lancet1865; ii:475
8
- Hirsch J, Hirsch BI. Paul Ehrlich and the discovery of the
eosinophil. In: Mahmoud AAF, Austen KF, eds. The Eosinophil in
Health and Disease. New York: Grune and Stratton,1980
: 323
- Osler W. Bronchial asthma. In: Principles and Practice
of Medicine. New York: D. Appleton & Co., 1892:497
501
- Huber HL, Koessler KK. The pathology of bronchial asthma.
Arch Intern Med1922; 30:689[Abstract/Free Full Text]
- Payne DN, Rogers AV, Adelroth E, et al. Early thickening
of the reticular basement membrane in children with difficult asthma.
Am J Respir Crit Care Med2003; 167:78
82[Abstract/Free Full Text]
- Holgate ST. Airway inflammation and remodeling in asthma: current
concepts. Mol Biotechnol2002; 22:179
89[Medline]
- Jarvis D, Burney P. Epidemiology of asthma. In: Busse WE, Holgate
ST, eds. Asthma and Rhinitis. Oxford: Blackwell
Science, 2000
- The International Study of Asthma and Allergies in Childhood
(ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of
asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC.
Lancet1998; 351:1225
32[Medline]
- Anonymous. Genes for asthma? An analysis of the European Community
Respiratory Health Survey. Am J Respir Crit Care Med1997; 156:1773
80[Abstract/Free Full Text]
- Viegi G, Annesi I, Malteel G. Epidemiology of asthma.
Eur Respir Monogr2003; 8:1
25
- Blackley CH. Experimental Researches on the Causes and
Nature of Catarrhus Aestivus (Hay-fever and Hay-asthma). London:
Baillière Tindall and Cox, 1873
- Stewart GA, McWilliam AS. Endogenous function and biological
significance of aeroallergens: an update. Curr Opin Allergy Clin
Immunol 2001;1:95
103[Medline]
- Holt PG, Stumbles PA. Regulation of immunologic homeostasis in
peripheral tissues by dendritic cells: the respiratory tract as a paradigm.
J Allergy Clin Immunol2000; 105:421
9[Medline]
- Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of
Th1/Th2 polarization. Immunol Today2000; 21:479
83[Medline]
- Lynch NR, Hagel I, Perez M, Di Prisco MC, Lopez R, Alvarez N.
Effect of anthelmintic treatment on the allergic reactivity of children in a
tropical slum. J Allergy Clin Immunol1993; 92:404
11[Medline]
- Vance GH, Holloway JA. Early life exposure to dietary and inhalant
allergens. Pediatr Allergy Immunol2002; 13(Suppl 15):14
18
- Umetsu DT, McIntire JJ, Akbari O, Macaubas C, Dekruyff RH. Asthma:
an epidemic of dysregulated immunity. Nat Immunol2002; 3:715
20[Medline]
- Holgate ST, Broide D. New targets for allergic rhinitisa
disease of civilization. Nature Rev Drug Discovery2003; 2:903
14
- Brunekreef B, Smit J, de Jongste J, et al. The prevention
and incidence of asthma and mite allergy (PIAMA) birth cohort study: design
and first results. Pediatr Allergy Immunol2002; 13(Suppl 15):55
60
- Woodcock A, Forster L, Matthews E, et al. Control of
exposure to mite allergen and allergen-impermeable bed covers for adults with
asthma. N Engl J Med2003; 349:225
36[Abstract/Free Full Text]
- Terreehorst I, Hak E, Oosting AJ, et al. Evaluation of
impermeable covers for bedding in patients with allergic rhinitis.
N Engl J Med2003; 349:237
46[Abstract/Free Full Text]
- Halken S, Host A, Niklassen U, et al. Effect of mattress
and pillow encasings on children with asthma and house dust mite allergy.
J Allergy Clin Immunol2003; 111:169
76[Medline]
- Carswell F, Birmingham K, Oliver J, Crewes A, Weeks J. The
respiratory effects of reduction of mite allergen in the bedrooms of asthmatic
childrena double-blind controlled trial. Clin Exp
Allergy 1996;26:386
96[Medline]
- Strachan DP. Hay fever, hygiene, and household size.
BMJ1989; 299:1259
60
- Riedler J, Braun-Fahrlander C, Eder W, et al. Exposure to farming
in early life and development of asthma and allergy: a cross-sectional survey.
Lancet2001; 358:1129
33[Medline]
- Braun-Fahrlander C, Riedler J, Herz U, et al.
Environmental exposure to endotoxin and its relation to asthma in school-age
children. N Engl J Med2002; 347:869
77[Abstract/Free Full Text]
- Vercelli D. Learning from discrepancies: CD14 polymorphisms, atopy
and the endotoxin switch. Clin Exp Allergy2003; 33:153
5[Medline]
- Horner AA, Van Uden JH, Zubeldia JM, Broide D, Raz E. DNA-based
immunotherapeutics for the treatment of allergic disease. Immunol
Rev 2001;179:102
18[Medline]
- Creticos P, et al. Immunotherapy with immunostimulatory
oligonucleotides linked to purified ragweed (Amba1 allergen): effects on
antibody production, nasal allergen provocation and ragweed seasonal rhinitis.
J Allergy Clin Immunol2002; 109:743
4
- Ikeda RK, Nayar J, Cho JY, et al. Resolution of airway
inflammation following ovalbumin inhalation: comparison of ISS DNA and
corticosteroids. Am J Respir Cell Mol Biol2003; 28:655
63[Abstract/Free Full Text]
- Hussain I, Jain VV, Kitagaki K, Businga TR, O'shaughnessy P, Kline
JN. Modulation of murine allergic rhinosinusitis by CpG oligodeoxynucleotides.
Laryngoscope2002; 112:1819
26[Medline]
- Prausnitz C, Küstner H. Studien über die
Ükerempfindlickkeit. Zentralb Bakteriol1921; 86:160
8
- Ishizaka K, Ishizaka T. Identification of gamma-E-antibodies as a
carrier of reaginic activity. J Immunol1967; 99:1187
98[Abstract/Free Full Text]
- Johansson SG, Bennich H. Immunological studies of an atypical
(myeloma) immunoglobulin. Immunology1967; 13:381
94[Medline]
- Holgate ST. The role of mast cells and basophils in inflammation.
Clin Exp Allergy2000; 30(suppl 1):28
32
- Corne J, Djukanovic R, Thomas L, et al. The effect of
intravenous administration of a chimeric anti-IgE antibody on serum IgE levels
in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin
Invest 1997;99:879
87[Medline]
- Djukanovic R, Wilson SJ, Kraft M, et al. Effect of
treatment with anti-IgE antibody on airway inflammation in mild asthma.
Eur Respir J2003; 22(suppl 45):203s
- Presta LG, Lahr SJ, Shields RL, et al. Humanization of an
antibody directed against IgE. J Immunol1993; 151:2623
32[Abstract]
- Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE
recombinant humanized monoclonal antibody, for the treatment of severe
allergic asthma. J Allergy Clin Immunol2001; 108:184
90[Medline]
- Lemanske RF, Jr., Nayak A, McAlary M, Everhard F, Fowler-Taylor A,
Gupta N. Omalizumab improves asthma-related quality of life in children with
allergic asthma. Pediatrics2002; 110:e55[Abstract/Free Full Text]
- Vernersson M, Ledin A, Johansson J, Hellman L. Generation of
therapeutic antibody responses against IgE through vaccination.
FASEB J2002; 16:875
7[Abstract/Free Full Text]
- James AL, Maxwell PS, Pearce-Pinto G, Elliot JG, Carroll NG. The
relationship of reticular basement membrane thickness to airway wall
remodeling in asthma. Am J Respir Crit Care Med2002; 166:1590
5[Abstract/Free Full Text]
- Schelegle ES, Gershwin LJ, Miller LA, et al. Allergic
asthma induced in rhesus monkeys by house dust mite (Dermatophagoides
farinae). Am J Pathol2001; 158:333
41[Abstract/Free Full Text]
- Plopper CG, Weir AJ, Wong VJ, et al. Stunting of
conducting airways induced in rhesus monkeys by ozone and/or allergen fails to
recover following cessation of exposure. Am J Respir Crit Care
Med 2003;167:A158
- Van Eerdewegh P, Little RD, Dupuis J, et al. Association
of the ADAM-33 gene with asthma and bronchial hyper-responsiveness.
Nature2002; 418:426
30[Medline]
- Umland SP, Garlisi CG, Shah H, et al. Human ADAM33 mRNA
expression profile and post-transcriptional regulation. Am J Respir
Cell Mol Biol 2003;29:571
82[Abstract/Free Full Text]
- Jongepier H, Boezen HM, Dijkstra A, et al. Polymorphisms
of the ADAM 33 gene are associated with decline in FEV1 in a dutch asthma
population. Am J Respir Crit Care Med2003; 167:A749
- John S, Jury FAC, Holloway J, et al. ADAM33 polymorphisms
predict early-life lung function: a population based cohort study.
Am J Hum Genet2003; 209:A37
- Gupta R, Sheikh A, Strachan D, Anderson HR. Increasing hospital
admissions for systemic allergic disorders in England: analysis of national
admissions data. BMJ2003; 327:1142
3[Free Full Text]
- Allen M, Heinzmann A, Noguchi E, et al. Positional cloning
of a novel gene influencing asthma from chromosome 2q14. Nat
Genet 2003;35:258
63[Medline]

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Kruschinski, T. Skripuletz, S. Bedoui, K. Raber, R. H. Straub, T. Hoffmann, K. Grote, R. Jacobs, M. Stephan, R. Pabst, et al.
Postnatal Life Events Affect the Severity of Asthmatic Airway Inflammation in the Adult Rat
J. Immunol.,
March 15, 2008;
180(6):
3919 - 3925.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Balicer, I. Grotto, M. Mimouni, and D. Mimouni
Is Childhood Vaccination Associated With Asthma? A Meta-analysis of Observational Studies
Pediatrics,
November 1, 2007;
120(5):
e1269 - e1277.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Tschopp, N. Spiegl, S. Didichenko, W. Lutmann, P. Julius, J. C. Virchow, C. E. Hack, and C. A. Dahinden
Granzyme B, a novel mediator of allergic inflammation: its induction and release in blood basophils and human asthma
Blood,
October 1, 2006;
108(7):
2290 - 2299.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-P. Boulet, C. Lemiere, F. Archambault, G. Carrier, M. C. Descary, and F. Deschesnes
Smoking and Asthma: Clinical and Radiologic Features, Lung Function, and Airway Inflammation
Chest,
March 1, 2006;
129(3):
661 - 668.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Alvarez, F. K. Swirski, T.-C. Yang, R. Fattouh, K. Croitoru, J. L. Bramson, M. R. Stampfli, and M. Jordana
Inhalation Tolerance Is Induced Selectively in Thoracic Lymph Nodes but Executed Pervasively at Distant Mucosal and Nonmucosal Tissues
J. Immunol.,
February 15, 2006;
176(4):
2568 - 2580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Mastrangelo, J. M. Grange, E. Fadda, U. Fedeli, A. Buja, and J. H. Lange
Lung Cancer Risk: Effect of Dairy Farming and the Consequence of Removing that Occupational Exposure
Am. J. Epidemiol.,
June 1, 2005;
161(11):
1037 - 1046.
[Abstract]
[Full Text]
[PDF]
|
 |
|